Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica

Journal of Rheumatology

Volumn 35, Issue 1, 2008, Pages 172-174

  Mok, Chi Chiu ^a   To, Chi Hung ^a   Mak, Anselm ^a   Poon, Wai Lun ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Cyclophosphamide; Immunoablative; Lupus; Neuromyelitis optica; Transplant; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MYELOOPTIC NEUROPATHY; OPTIC NERVE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEUROMYELITIS OPTICA; RECURRENCE;

EID: 38149037133     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gibbs AN, Moroney J, Foley-Nolan D, O'Connell PG. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology Oxford 2002;41:470-1.
2. Jacobi C, Stingele K, Kretz R, et al. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus 2006;15:107-9.
3. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 2007;20:255-60.
4. Ghezzi A, Bergamaschi R, Martinelli V, et al; Italian Devic's Study Group (IDESG). Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol 2004;251:47-52.
5. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-7.
6. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43.
7. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
8. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007;13:2-11.
10. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
11. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-6.
12. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-63.
13. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
14. Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 2005;19:839-58.
15. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-73.